

CLAIMS

1. A conjugate comprising:
  - (a) a first region comprising the homeodomain of antennapedia or a functional variant thereof; and
  - 5 (b) a second region not naturally associated with the first region; and wherein at least the first region is non-denatured.
- 10 2. ~~The~~ conjugate according to claim 1, wherein the first and second regions are associated via a disulfide bond.
- 15 3. ~~The~~ conjugate according to claim 1, in the form of a fusion protein.
- 20 4. ~~The~~ conjugate according to ~~any preceding claim~~, wherein the second region comprises a protein of at least 100 amino acids.
- 25 5. ~~The~~ conjugate according to claim 4, wherein the second region is a functional or regulatory protein.
6. ~~The~~ conjugate according to claim 4, wherein the second region is an antigen.
- 30 7. ~~The~~ conjugate according to claim 4, wherein the second region is a DNA binding domain.
8. ~~The~~ conjugate according to claim 7, wherein the second region further comprises an NOI.
- 35 9. ~~The~~ conjugate according to claim 1 ~~or claim 2~~, wherein the second region comprises an NOI.
- 25 10. ~~Nucleic acid~~ encoding ~~a~~ conjugate according to ~~any preceding claim~~ —  
~~claim 1~~
11. An expression vector, comprising the nucleic acid of claim 10, operably linked to a promoter.
12. A host cell transformed with the expression vector of claim 11.
- 30 13. A method for preparing a conjugate according to ~~any of claims 1 to 9~~, comprising:
  - (i) culturing a host cell according to claim 12 under conditions which provide for the expression of the conjugate within the host cell; and
  - 35 (ii) recovering the conjugate by affinity purification under non-denaturing conditions.

- A
- The  
14. A method according to claim 13, wherein the conjugate comprises an amino acid tail that binds to an immobilised substrate.
- 5 15. A conjugate prepared according to the method of claim 13 or claim 14.
- B
16. A pharmaceutical composition comprising the conjugate of any one of claims 1 to 9 or claim 15, in combination with a pharmaceutically-acceptable carrier.
- P
17. The pharmaceutical composition according to claim 16, in the form of a vaccine.
- D
18. Use of the conjugate of any one of claims 1 to 9 or claim 15, in the preparation of a medicament for the treatment or prevention of cancer, a genetic disease and bacterial or viral infection.
- 15 19. The conjugate according to any one of claims 1 to 9 or claim 15, for use in an expression system.

Claim 1

A1  
Add

add D1 → add E1 →